Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNA Nat-B env
- Development stage
- Phase 1
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
DNA Nat-B env is a DNA vaccine component containing an HIV-1 envelope insert. It is designed to be part of a prime-boost HIV vaccine regimen, where it serves as the DNA prime vaccine. The vaccine aims to evaluate its safety, tolerability, and ability to elicit an immune response against HIV-1 in healthy, HIV-uninfected adults. It has been studied in clinical trials in combination with other boost vaccines like NYVAC Nat-B env or MVA-CMDR.
- Other names
- DNA Nat-B env
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on DNA Nat-B env.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA Nat-B env.